Asia · Markets & Finance · The Investor

Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

Published by The Investor · South Korea 22 h ago

Hanmi Pharmaceutical’s Eppe is poised to challenge Wegovy and Mounjaro in Korea’s fast-growing obesity drug market, with price emerging as a potentially decisiv ...

Read the full article on The Investor Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.theinvestor.co.kr)

Also worth reading

Mint

Best bank stock to buy amid Q2 business updates: PNB, Canara, Union Bank, Indian Bank or Bandhan? Target Prices

The Business Times

Hao Mart owner resisting OG’s mortgage foreclosure on his GCB

CNBC-TV18

Nifty Outlook for October 6: Will bears use index bounce as a selling opportunity on weekly expiry?

Business Standard

TVS ASL raises ₹425 crore from Crescent Enterprises in Series D round

The Economic Times

Is joining EPS a must at Rs 25K+ salary?

SCMP Business